Nuevos fármacos para el tratamiento de la diabetes tipo 2

Revista Clinica Espanola

Volumn 200, Issue 3, 2000, Pages 151-156

  Puigdevall Gallego, V ^a   Laudo Pardos, C ^b,c   Del Rio Mayor M J ^b   Velasco Martin A ^b  

^a Hospital General del Insalud Soria   (Spain)

^b UNIVERSITY OF VALLADOLID   (Spain)

^c Escuela Univ di Fisioterapia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIOBESITY AGENT; ACARBOSE; GLUCAGON LIKE PEPTIDE 1; METFORMIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SIBUTRAMINE; SOMATOMEDIN C; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; TROGLITAZONE; VOGLIBOSE;

CLASSIFICATION; DRUG COMBINATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; DIABETES CONTROL; DRUG CLASSIFICATION; DRUG MECHANISM;

ANTI-OBESITY AGENTS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 0034037242     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2565(00)70588-1     Document Type: Review

References (54)

1. The Diabetes Control and Complication Trial Research Group: the effect of intensive treatment of diabetes on the developement and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
2. Nathan DM. Some answers, more controversy, from UKPDS. Lancet 1998; 352:832-834.
3. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28:103-117.
4. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 1999 (suppl 1):S27-S31.
5. Aguilar-Bryan L, Nichols CG, Weschler SW, et al. Cloning of the b cell high-affinitty sulfonilurea receptor: a regulator of insulin secretion. Science 1995; 268: 423-426.
6. Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am 1997, 26:511-522.
7. Garratt KN, Hassinger N, Grill DE. Sulfonylurea drug use is associated with increased early mortality during direct coronary angioplasty for acute myocardial infarction among diabetic patients. J Am Coll Cardiol 1997, 29: 493A (abstr).
8. Schade DS, Jovanovic L, Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol 1998; 38:636-641.
9. Draeger E. Clinical profile of glimepiride. Diabetes Res Clin Pract 1995; 28 (suppl):S139-S146.
10. Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47:345-351.
11. Leclercq-Meyer V, Ladriere L, Fuhlendorff J, Malaisse WJ. Stimulation of insulin and somatostatin release by two meglitinide analogs. Endocrine 1997; 7:311-317.
12. Owens DR. Repaglinide-prandial glucose regulator: a new class of oral antidiabetic drugs. Diabet Med 1998; 15 (suppl 4):S28-S36.
13. Goldberg RB, Einhorn D, Lucas CP, et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998; 21:1.897-1.903.
14. Wolffenbuttel BH, Landgraf RA. 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 1999; 22:463-467.
15. Balfour JA, Faulds D. Repaglinide. Drugs Aging 1998; 13:173-180.
16. Willms B, Idowu K, Holst JJ, Creutzfeldt W, Nauck MA. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients. Exp Clin Endocrinol Diabetes 1998; 106:103-107.
17. Rachman J, Barrow BA, Levy JC, Turner RC. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997; 40:205-211.
18. Nauck MA, Holst JJ, Willms B. Glucagon-like peptide 1 and its potential in the treatment of non insulin dependent diabetes mellitus. Horm Metab Res 1997; 29:411-416.
19. Bailey CJ, Path MRC, Turner R. Metformin. N Engl J Med 1996; 334: 574-579.
20. Stumvoll M, Nurjhan N, Perriello G, Failey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:550-554.
21. Marena S, Taglialerro V, Montegrosso G, Pagano A, Scaglione L, Pagano G. Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes. Diabete Metab 1994; 20:15-19.
22. De Fronzo RA, Goodman AM, Multicenter Metformin Study Group. Efficacy of metformin in patients with non insulin dependent diabetes mellitus. N Engl J Med 1995; 333:541-549
23. Brown JB, Pedula K, Barzilay J, Herson MK, Latare P. Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998; 21:1.659-1.663.
24. Bell PM, Hacden DR. Metformin. Endocrinol Metab Clin North Am 1997; 26:523-538.
25. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999; 16:179-192.
26. Saltier AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45:1.661-1.669.
27. Schwartz S, Raskin P, Fonseca V, Graveline JF. for the Troglitazone and Exogenous Insulin Study Group. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 1998; 338:861-868.
28. Buysschaert M, Bobbioni E, Starkie M, Frith L. Troglitazone in combination with sulphonylurea improves glycaemic control in type 2 diabetic patients inadequately controlled by sulfonylurea therapy alone. Troglitazone Study Group. Diabet Med 1999; 16:147-153.
29. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Shulman GI. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338:867-872.
30. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996; 19:151-156.
31. Buse JB, Gumbiner B, Mathias NP, Nelson DM, Faja BW, Whitcomb RW. the Troglitazone Study Group. Troglitazone use in insulin-treated type 2 diabetes patients. Diabetes Care 1998; 21:1.455-1.461.
32. De Pablos PL, Martinez MP. Los agentes orales: antiguas y nuevas perspectivas. Av Diabetol 1999: 15(S):46-48.
33. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338:916-917.
34. Saleh YM, Mudaliar SR, Henry RR. Metabolic and vascular effects of the thiazolidinedione troglitazone. Diabetes Rev 1999; 7:55-76.
35. Riddle MC. Learning to use Troglitazone. Diabetes Care 1998; 21: 1.389-1.390.
36. Umeda F. Potential role of thiazolidinediones in older diabetic patients. Drugs Aging 1995; 7:331-337.
37. Chaiken RC, Eckert-Norton M, Pasmantier R, et al. Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects. Diabetologia 1995; 38:1.307-1.312.
38. Patel J, Miller E, Patwardhan R, The Rosiglitazone Oil Study Group. Rosiglitazone (BRL49653) monotherapy has significant glucose lowering effect in type 2 diabetic patients. Diabetes 1998; 47 (suppl 1):67A (Abstr).
39. Mukherjee R, Davies RJ, Crombie DL, et al. Sensitizacion of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997; 386:407-410.
40. Thraikill KM, Quanttrin T, Baker L, Kuntze JE, Compton PG, Martha PM Jr. Cotherapy with recombinant human insulin-like growth factor 1 and insulin improves glycaemic control in type 1 diabetes. RhIGF-I in IDDM Study Group. Diabetes Care 1999; 22:585-592.
41. Moses AC, Young SCJ, Morrow LA, O'Brian M, Clemmons DR. Recombinant human insulin-like growth factor-1 increases insulin sensitivity and improves glycaemic control in type II diabetes? Diabetes 1996; 45: 91-100.
42. Zhang B, Salituro G, Szalkowski D, et al. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science 1999; 284:974-977.
43. Meyerovitch J, Rothenberg P, Schlechter Y, Bonner-Weir S, Kahn CR. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. J Clin Invest 1991; 87:1.286-1.294.
44. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter placebo-controlled trial comparing acarbose with placebo, tolbutamide and tolbutamide plus acarbose in NIDDM. Am J Med 1995; 98:443-445.
45. Costa B. Acarbosa y diabetes ¿modesta mejoria o autentico avance terapéutico? Med Clin (Barc) 1995; 105:341-343.
46. Fujimoto Y, Ohhira M, Miyokawa N, Kitamori S, Kongo Y. Acarbosa-induced hepatic injury. Lancet 1998; 351:340.
47. Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycaemia. Drugs 1999; 57:19-29.
48. Lebovitz HE. Alpha-glucosidase inhibitors. Endocrinol Metab Clin North Am 1997; 26:539-552.
49. Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, Munera CL. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998; 83: 1.515-1.522.
50. Lebovitz HE. Alfa-glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998; 6:132-145.
51. Thompson RG, Pearson L, Schoenfeld SL, Kolterman OG. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group. Diabetes Care 1998; 21:987-993.
52. American Diabetes Association. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1996 (suppl 1):54-61.
53. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21:1.288-1.294.
54. Lean ME. Sibutramine a review of clinical efficacy. Int J Obes Relat Metab Disord 1997; 21 (suppl 1):S30-S36.